Q Labs INC

Q Labs INC was paid $8.76M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 31% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in West Virginia

Rank by total paid#6 of 36

Median peer was paid$61K

This provider vs. median143×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	17,095	$648K
2019	21,281	$1.23M
2020	24,011	$2.42M
2021	48,041	$1.51M
2022	30,253	$908K
2023	40,732	$1.03M
2024incomplete	45,709	$1.01M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	31%	30,690	18,166	$2.68M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	26%	38,472	24,068	$2.29M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	17%	43,787	25,313	$1.49M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	10%	28,522	19,091	$886K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	9.0%	16,434	12,672	$792K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.9%	12,376	9,074	$169K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.1%	1,043	768	$99K
87900		<1%	1,171	877	$44K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	2,019	1,053	$24K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	229	142	$20K
87481		<1%	861	628	$20K
80074		<1%	1,063	922	$18K

102 more codes

80053	Comprehensive metabolic panel	<1%	4,534	$11K
80061	Lipid panel	<1%	2,730	$11K
84443	Thyroid stimulating hormone (TSH)	<1%	3,064	$10K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,518	$10K
80050	General health panel	<1%	641	$9K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,818	$9K
87640		<1%	861	$8K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,902	$8K
87653		<1%	718	$7K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	320	$7K
82607		<1%	1,325	$6K
87529		<1%	361	$6K
87522	Neg quan hep c or qual rna	<1%	371	$6K
87625		<1%	365	$5K
81025		<1%	146	$5K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	364	$5K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	360	$5K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	344	$4K
87563		<1%	421	$4K
86703		<1%	839	$4K
87511		<1%	306	$3K
86780		<1%	619	$3K
36415	Collection of venous blood by venipuncture	<1%	1,808	$3K
84481		<1%	451	$3K
87806		<1%	175	$2K
80362		<1%	521	$2K
80372		<1%	522	$2K
80354		<1%	522	$2K
80366		<1%	520	$2K
80373		<1%	522	$2K
80348		<1%	522	$2K
80355		<1%	522	$2K
80346		<1%	477	$2K
80361		<1%	477	$2K
80349		<1%	483	$2K
80358		<1%	477	$2K
80359		<1%	476	$2K
80353		<1%	477	$2K
80324		<1%	478	$2K
80356		<1%	477	$2K
80365		<1%	477	$2K
80370		<1%	476	$2K
80360		<1%	453	$2K
80368		<1%	469	$2K
87581		<1%	184	$2K
80345		<1%	475	$2K
84439		<1%	586	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	1,303	$1K
85027		<1%	852	$1K
80164		<1%	328	$1K
87500		<1%	44	$1K
87641		<1%	44	$1K
86708		<1%	211	$1K
86704		<1%	211	$1K
87496		<1%	40	$1K
81596		<1%	48	$1K
83735		<1%	626	$1K
87662		<1%	21	$993.41
86706		<1%	214	$978.86
83992		<1%	477	$953.31
87556		<1%	23	$847.81
83540		<1%	442	$798.85
87631		<1%	36	$767.37
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	39	$629.16
83550		<1%	253	$583.77
84146		<1%	123	$578.81
80076		<1%	299	$546.42
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	17	$508.71
82746		<1%	135	$473.36
80321		<1%	82	$398.02
87086	Culture, bacterial; quantitative colony count, urine	<1%	228	$368.86
87634		<1%	17	$341.16
84436		<1%	486	$330.84
83880		<1%	46	$328.41
84403		<1%	28	$319.32
82728		<1%	126	$315.65
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	40	$230.90
87498		<1%	18	$211.57
82043		<1%	149	$208.61
87486		<1%	17	$186.31
87541		<1%	17	$186.31
82977		<1%	127	$166.76
87503		<1%	17	$155.17
80177		<1%	50	$143.16
81001		<1%	83	$110.61
86140		<1%	63	$104.86
81003		<1%	216	$103.79
84153		<1%	22	$102.67
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	13	$95.73
84479		<1%	233	$73.29
82570		<1%	33	$60.58
86803		<1%	126	$52.17
82248		<1%	73	$49.54
85652		<1%	46	$39.97
87340		<1%	120	$29.59
86705		<1%	121	$28.20
80178		<1%	17	$21.12
85004		<1%	213	$9.67
85008		<1%	147	$1.49
85009		0%	157	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	471	$0.00
86709		0%	113	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCOLLINS, MARY (CFO)

Same official

Other billing entities under COLLINS, MARY

Full network →

Provider	Location	Paid
Statesboro Ob-Gyn Specialists, PC	Statesboro, GA	$24K
Collins Counseling & Associates, P.C.	Mobile, AL	$9K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.